TSHA - Taysha Gene Therapies Inc logo

TSHA

Taysha Gene Therapies Inc

Rev —top 1%5Y
Hold

Taysha Gene Therapies develops adeno-associated virus-based gene therapies targeting severe monogenic diseases of the central nervous system, including treatments for disorders like Rett syndrome and giant axonal neuropathy.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $367today

Score Overview

1 Year
Score
Net Growth-19.16%
Net TrendShrank
Net Income Consistency
Rev Growth-23.55%
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth25.58%
Net Trend60%
Net Income Consistency
Rev Growth
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-202.04%
Net Trend50%
Net Income Consistency
Rev Growth
Rev Trend50%
Revenue Consistency

See the full market ranking →

Taysha Gene Therapies Inc fundamental performance

Across Taysha Gene Therapies Inc's full reported history, from 2020 to 2025, revenue grew from $ 0.00 to $ 9M and net income went from -$ 43M to -$ 108M. Revenue increased in 50% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 6.41
1 Year2025-08-12
$ 2.91120.10%
5 Years2021-08-12
$ 17.47-63.34%
All Time2020-09-24
$ 24.06-73.38%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 7M-$ 129M$ 276M
2025$ 9M-$ 108M$ 319M
2024$ 8M-$ 89M$ 139M
2023$ 15M-$ 111M$ 143M
2022$ 2M-$ 166M$ 87M
2021$ 0.00-$ 174M$ 149M
IPO2020$ 0.00-$ 43M$ 251M

Explore beyond TSHA

You're looking at Taysha Gene Therapies Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies